Previous 10 | Next 10 |
2023-12-15 17:36:27 ET More on Kazia Kazia Therapeutics falls after announcing $2M direct offering Kazia stock jumps after proposed license deal for paxalisib outside oncology Historical earnings data for Kazia Financial information for Kazia For furt...
IMV Inc. (IMVIQ) is expected to report for Q3 2023 Orbit International Corp. (ORBT) is expected to report for quarter end 2023-09-30 PLx Pharma Winddown Corp. (PLXPQ) is expected to report for quarter end 2023-09-30 Advantage Energy Ltd (AAVVF) is expected to report for Q1 2024 We...
lululemon athletica inc. (LULU) is expected to report $2.27 for Q3 2024 Arco Platform Limited (ARCE) is expected to report $-0.17 for Q3 2023 Elekta AB ADR (EKTAY) is expected to report for Q2 2024 Kimberly - Clark de Mexico S.A. ADR (KCDMY) is expected to report for Q1 2024 Torri...
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering PR Newswire SYDNEY , Dec. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the...
2023-12-01 09:04:12 ET More on Kazia Kazia stock jumps after proposed license deal for paxalisib outside oncology Kazia issues update on paxalisib study in CNS lymphoma patients For further details see: Kazia Therapeutics falls after announcing $2M direct offering
Kazia Therapeutics Announces $2 Million Registered Direct Offering PR Newswire SYDNEY , Dec. 1, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it h...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
2023-11-29 07:49:55 ET Kazia Therapeutics ( NASDAQ: KZIA ) has signed a non-binding letter of intent with an undisclosed biotech firm for the proposed granting of worldwide rights to develop and commercialize its lead candidate, paxalisib, in an indication outside of cancer. ...
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY PR Newswire SYDNEY , Nov. 29, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug deve...
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING PR Newswire SYDNEY , Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is please...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...